Reading LMAT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LMAT free→Reading LMAT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LMAT free→NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, and management's recent track record has been steady. Earnings quality is neutral, and risk is moderate, while the sector backdrop is a headwind. Compared with sector peers, LMAT is above typical. Peer multiples imply a price about 38% below where it trades (it looks expensive on this basis); the read is expensive, growth-justified, as it is rich on today's multiple, but the three-year horizon reads cheaper once expected earnings growth is included. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 8 valuation methods, at three horizons. Current price $93.39. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $93 the market pays 34× p/e — above the 23× p/e peer median but in line with its own 45× history. That premium reflects a durable franchise our peer-anchored $68 fair value understates; treat the 'expensive vs peers' read with medium confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 38% near-term growth, ahead of our forecast of about 15%. This describes what's priced in, not a forecast of the move.
Only weak execution quality — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 1.40x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 50% for the rest of the cohort, n=2269).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity, the US dollar.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.76 → $0.81 (+6.7% / 30d). 7 raised, 0 cut, 9 covering analysts.
0 upgrades, 0 downgrades / 30d, 1 maintained. 56% of analysts rate Buy.
Market and fundamentals agree. Analysts are positioned bullishly on a fundamentally strong name.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$133.
How much price usually moves either way.
On a bad day, this stock has moved -$282.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $2,212.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: A decline below this level may indicate rising costs or pricing pressures.
Confirms:Gross margin reported below 72.1% for Q2 2026.
Disproves:Gross margin reported above 72.1% for Q2 2026.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for LMAT yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On May 5, 2026, LeMaitre Vascular, Inc. (the “Company”) issued a press release regarding its preliminary financial and operational results for the quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Report. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Looks more expensive than peers.
Cheaper than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Equipment.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
LMAT LeMaitre Vascular | Above typical Show detailsSector percentile: 95 of 100 | expensive | moderate |
ABT Abbott Laboratories | Above typical Show detailsSector percentile: 92 of 100 | fair | moderate |
ISRG Intuitive Surgical | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
SYK Stryker Corporation | Above typical Show detailsSector percentile: 71 of 100 | fair | moderate |
MDT Medtronic | Above typical Show detailsSector percentile: 89 of 100 | fair | moderate |
2 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Met or beat guidance 100% of the last 2 guided quarters · 18.4% avg surprise
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on achieving higher revenue growth through strategic initiatives.
Improve operating income through cost management and efficiency.
Commitment to increasing shareholder returns through higher dividends.
Why it matters: Keeping the dividend shows the company is stable. It shows they care about shareholders.
Confirms:Quarterly dividend remains at $0.25 per share.
Disproves:Dividend cut below $0.25 per share.
Why it matters: If sales fall below $70.5 million, it may signal weakening demand.
Confirms:Q2 2026 sales reported below $70.5 million.
Disproves:Q2 2026 sales reported above $72.5 million.
Why it matters: Meeting this growth target would show LeMaitre is on track with its revenue goals. It would also help offset recent earnings concerns.
Confirms:Q2 revenue growth meets or exceeds 10% year over year.
Disproves:Q2 revenue growth falls below 5% year over year.
Why it matters: Better margins show good cost control. This helps increase operating income.
Confirms:Operating income margin is over 27% in Q2.
Disproves:Operating income margin drops below 25% in Q2.
Why it matters: Exceeding this growth rate would show strong cost management and demand.
Confirms:Operating income grew more than 34% in Q2 2026.
Disproves:Operating income grew less than 34% in Q2 2026.
Why it matters: A drop below median growth would signal a slowdown in the sector's expansion.
Confirms:Revenue growth falls below the median of 10% year over year.
Disproves:Revenue growth remains at or above the median of 10% year over year.
Why it matters: A rise shows confidence in cash flow and making money.
Confirms:Announcement of a dividend increase above $0.25 per share.
Disproves:No dividend increase announced in Q2 2026.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On April 8, 2026, Bridget Ross notified the Board of Directors (the “Board”) of LeMaitre Vascular, Inc. (the “Company”) of her intent not to stand for re-election as a Class II director of the Company at the Company’s 2026 Annual Meeting of Stockholders to be held on June 2, 2026 (the “2026 Annual Meeting”). Ms. Ross will continue to serve as a…
Other Events. The Company’s Second Amended and Restated Certificate of Incorporation and Second Amended and Restated By-laws provide that the size of the Board shall be determined from time to time by resolution of the Board. As a result of the events described in Item 5.02, the Board has taken action to reduce the size of the Board from eight to seven members, effective immediately upon Ms. Ross’s departure from the Board. In this regard, effective as of the conclusion of the 2026 Annual Mee…
Results of Operations and Financial Condition. On February 25, 2026, LeMaitre Vascular, Inc. (the “Company”) issued a press release regarding its preliminary financial and operational results for the quarter ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Report. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Ac…